A recent study has illuminated the connections between pituitary neuroendocrine tumors (PitNETs) and cognitive deficits, particularly in memory, attention, and executive function. Conducted by researchers at Kunming Medical University, the study suggests that hormonal dysregulation and alterations in gut microbiota may play significant roles in these cognitive impairments. The findings, published online on December 30, 2025, in Volume 11, Issue 33 of the Chinese Neurosurgical Journal, challenge traditional beliefs that attribute cognitive decline primarily to tumor size and mass effects.
Dr. Xingli Deng, who led the study, explained the rationale: “By integrating neurocognitive assessment with endocrine profiling and microbiome analysis, we aimed to move beyond traditional explanations centered solely on tumor size and mass effect, and instead explore a more comprehensive, biologically grounded model of cognitive dysfunction in PitNET patients.”
The prospective cross-sectional study involved 42 patients with PitNETs and an equal number of matched healthy controls. Cognitive function was measured using the Montreal Cognitive Assessment (MoCA) both before surgery and three months postoperatively. Researchers recorded tumor characteristics, including volume and invasiveness via MRI, and collected data on pituitary hormone levels. Tumors were categorized as functional or nonfunctional and further grouped by molecular lineage, specifically noting PIT1 and SF-1 classifications.
Significant findings emerged from the cognitive assessments. Patients diagnosed with PitNETs exhibited markedly lower cognitive performance than their healthy counterparts, with deficits most pronounced in areas such as attention, executive function, and memory. Dr. Deng highlighted that impairments were particularly severe among those with functional tumors, especially within the PIT1 lineage. Interestingly, the study revealed no significant correlation between tumor volume or invasiveness and cognitive outcomes, suggesting a need to rethink the factors contributing to neurocognitive decline.
After surgical intervention, cognitive scores improved notably over the three-month period, coinciding with reductions in elevated hormone levels like growth hormone (GH), insulin-like growth factor 1 (IGF-1), and prolactin (PRL). These results indicate a potential endocrine mechanism that underlies both cognitive dysfunction and recovery.
Another critical aspect of the research involved gut microbiota analysis, which exposed distinct changes in bacterial composition among patients with PitNETs. A significant reduction in the abundance of Agathobacter, a butyrate-producing genus known for its anti-inflammatory properties, was observed. In contrast, levels of pro-inflammatory taxa such as Alistipes indistinctus and UBA1819 were elevated. These shifts suggest that inflammatory and metabolic pathways associated with gut microbiota alterations may interact with hormonal imbalances, influencing cognitive health.
The comprehensive nature of this study, integrating clinical, endocrine, cognitive, and microbiome data within a well-characterized cohort, marks a significant advancement in understanding the multifactorial basis of cognitive dysfunction in PitNET patients. By establishing connections between tumor lineage and microbiota alterations, it provides an alternative perspective that extends beyond conventional structural explanations.
Despite the promising findings, the authors caution that the modest sample size and cross-sectional design limit the generalizability and causative implications of the results. Larger longitudinal studies are necessary to explore the causality further and assess whether targeting microbiota could enhance cognitive outcomes in conjunction with surgical interventions.
In summary, cognitive impairment is prevalent among patients with PitNETs, particularly those with PIT1-lineage tumors. The study emphasizes that cognitive dysfunction is more closely linked to hormonal dysregulation and changes in gut microbiota than to traditional measures of tumor burden. Surgical treatment appears to facilitate cognitive improvement, while exploring the modulation of the gut-brain axis could present new therapeutic opportunities. This research lays the groundwork for future integrated treatment strategies aimed at improving neurological function and enhancing quality of life for individuals affected by PitNETs.
